 | • レポートコード：B-MOR-08299 • 出版社/出版日：Mordor Intelligence / 2018年5月1日 • レポート形態：英文、PDF、112ページ • 納品方法：Eメール（受注後2営業日） • 産業分類：Healthcare |
| Single User（1名様用） | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User（7名様用） | ￥666,000 (USD4,500) | ▷ お問い合わせ |
| Corporate User | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、腎臓がん治療薬および診断の世界市場について調べ、腎臓がん治療薬および診断の世界規模、市場動向、市場環境、がんの種類別（腎細胞がん、淡明細胞型腎細胞がん、乳頭状腎細胞がん、嫌色素性腎細胞がん、その他）分析、治療別（アンフィニトール、アバスチン、インライタ、ネクサバール、プロロイキン、ヴォトリエント、スーテント）分析、診断別分析、エンドユーザー別分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。 ・イントロダクション ・エグゼクティブサマリー ・腎臓がん治療薬および診断の世界市場インサイト ・腎臓がん治療薬および診断の世界市場環境 ・腎臓がん治療薬および診断の世界市場動向 ・腎臓がん治療薬および診断の世界市場規模 ・腎臓がん治療薬および診断の世界市場規模：がんの種類別（腎細胞がん、淡明細胞型腎細胞がん、乳頭状腎細胞がん、嫌色素性腎細胞がん、その他） ・腎臓がん治療薬および診断の世界市場規模：治療別（アンフィニトール、アバスチン、インライタ、ネクサバール、プロロイキン、ヴォトリエント、スーテント） ・腎臓がん治療薬および診断の世界市場規模：診断別 ・腎臓がん治療薬および診断の世界市場規模：エンドユーザー別 ・腎臓がん治療薬および診断の世界市場：地域別市場規模・分析 ・腎臓がん治療薬および診断の北米市場規模・予測 ・腎臓がん治療薬および診断のアメリカ市場規模・予測 ・腎臓がん治療薬および診断のヨーロッパ市場規模・予測 ・腎臓がん治療薬および診断のアジア市場規模・予測 ・腎臓がん治療薬および診断の日本市場規模・予測 ・腎臓がん治療薬および診断の中国市場規模・予測 ・腎臓がん治療薬および診断のインド市場規模・予測 ・腎臓がん治療薬および診断の韓国市場規模・予測 ・関連企業情報・競争状況 |
The market for the period 2018 – 2023 is expected to register a CAGR of 10.5%. Kidney cancer is one of the frequent urologic cancers. The rate of renal cell carcinoma has increased gradually in the past few years. The growth of the Global Kidney Cancer Diagnostics and Therapeutics Market is mainly driven by factors, such as rising aging population, Changes in lifestyle, such as increased intake of alcohol and disproportionate smoking, and government policies to provide better care for Kidney Cancer.
Rising Number of Kidney Cancer Cases
The need for early identification of these diseases will lead to the growth in the market for kidney cancer therapeutics and diagnostics.Increasing detection of presymptomatic tumors by imaging procedures, such as ultrasonography, computed tomography, and magnetic resonance imaging, does not fully explain the upward incidence trends of renal cell carcinoma. Other factors, such as increased R&D expenditure of pharmaceutical companies and increasing incidences of chronic diseases and aging population will lead to the growth of the market in the forecast period.
High Cost Associated With Treatment
Kidney cancer drugs are very expensive to move findings from development stage to the market for commercial use because of all the regulatory studies involved to gain approvals. With the introduction of an approved new drug, the older drug, which is by now generic may be viewed as a substandard form of treatment, thereby, adding to the situation. In cases where Regulatory bodies, like FDA might want to consider taking economy and cost-effectiveness into account, when approving new drugs, there are certain legal barriers to prevent them from doing so. Because, most of the kidney cancer cases are diagnosed at the end stage, the seriousness of cancer and its diagnosis plays an important role in the decision of the patients and physicians to go about paying the high price of treatment even for marginal improvements in outcome. This may act as a restraining factor for the growth of kidney cancer therapeutics and diagnostics market. Other factors, such as low success rate in clinical trials for cancer drugs and regulatory issues will lead to the slowdown of the market.
North America to Dominate Market
North America region has the largest share in the global kidney cancer therapeutics and diagnostics market. Rising numbers of kidney cancer cases and other kidney diseases is the major element driving the growth in this region. However, Asia-Pacific is expected to be the most rewarding market during the forecast period. Growing patient awareness, lower cost of drug production and the rising patient base suffering from diseases, such as renal cell carcinoma are anticipated to drive the growth of the market in this region.
Key Developments in the Market
• November 2017 – The U.S. Food and Drug Administration today approved Sutent (sunitinib malate) for the adjuvant treatment of adult patients who are at high risk of kidney cancer (renal cell carcinoma) returning after a kidney has been removed (nephrectomy)
Major players- BAYER, F. HOFFMANN-LA ROCHE, GLAXOSMITHKLINE, NOVARTIS, PFIZER, ABBOTT LABORATORIES, AMGEN, GENENTECH, CERULEAN PHARMA AND SEATTLE GENETICS, amongst others.
Reasons to Purchase this Report
• Current and future global kidney cancer therapeutics & diagnostics market outlook in the developed and emerging markets
• Analysis of various perspectives of the market with the help of Porter’s five forces analysis
• The segment that is expected to dominate the market
• Regions that are expected to witness the fastest growth during the forecast period
• Identify the latest developments, market shares, and strategies employed by the major market players
• 3 months analyst support, along with the Market Estimate sheet (in Excel)
Customization of the Report
• This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs
レポート目次1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Rising Number of Kidney Cancer Cases
6.1.2 Increased R&D Expenditure of Pharmaceutical Companies
6.1.3 Increasing Incidences of Chronic Diseases and Aging Population
6.2 Market Restraints
6.2.1 High Cost Associated with Treatment
6.2.2 Low Success Rate in Clinical Trails for Cancer Drugs
6.2.3 Regulatory Issues
6.3 Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 By Cancer Type
7.1.1 Renal Cell Carcinoma
7.1.2 Clear Cell Renal Cell Carcinoma
7.1.3 Papillary Renal Cell Carcinoma
7.1.4 Chromophobe Renal Cell Carcinoma
7.1.5 Others
7.2 By Therapy
7.2.1 Afinitor
7.2.2 Avastin
7.2.3 Inlyta
7.2.4 Nexavar
7.2.5 Proleukin
7.2.6 Votrient
7.2.7 Sutent
7.3 By Diagnostics
7.3.1 Biopsy
7.3.2 Intravenous pyelogram
7.3.3 CT Scan
7.3.4 Nephro-ureteroscopy
7.3.5 Ultrasound
7.3.6 Others
7.4 By End Users
7.4.1 Hospitals
7.4.2 Pharmaceutical Labs
7.4.3 Genomics Laboratories
7.4.4 Others
7.5 By Geography
7.5.1 North America
7.5.1.1 United States
7.5.1.2 Canada
7.5.1.3 Mexico
7.5.2 Europe
7.5.2.1 France
7.5.2.2 Germany
7.5.2.3 United Kingdom
7.5.2.4 Italy
7.5.2.5 Spain
7.5.2.6 Rest Of Europe
7.5.3 Asia-Pacific
7.5.3.1 China
7.5.3.2 Japan
7.5.3.3 India
7.5.3.4 Australia & New Zealand
7.5.3.5 South Korea
7.5.3.6 Rest of Asia-Pacific
7.5.4 Middle East & Africa
7.5.4.1 GCC
7.5.4.2 South Africa
7.5.4.3 Rest of the Middle East & Africa
7.5.5 South America
7.5.5.1 Brazil
7.5.5.2 Argentina
7.5.5.3 Rest of South America
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.1 Abbott Laboratories
9.2 Amgen
9.3 Bayer Healthcare
9.4 Cerulean Pharma
9.5 F. Hoffmann-La Roche
9.6 Genentech
9.7 GlaxoSmithKline
9.8 Novartis
9.9 Pfizer
9.10 Seattle Genetics
9.11 List Not Exhaustive
10. Future of the Market